Prognostic factors for survival in patients with completely resected pN2 non-small-cell lung cancer

References

• Howington JA, Blum MG, Chang AC, et al. Treatment of stage I and II non-small cell lung cancer: diagnosis and management of lung cancer: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143:e278S–e313S.
   PubMed Web of Science ®Google Scholar
• Metin M, Citak N, Sayar A, et al. The role of extended cervical mediastinoscopy in staging of non-small cell lung cancer of the left lung and a comparison with integrated positron emission tomography and computed tomography: does integrated positron emission tomography and computed tomogr. J Thorac Oncol. 2011;6:1713–1719.
   PubMed Web of Science ®Google Scholar
• Misthos P, Sepsas E, Athanassiadi K, et al. Skip metastases: analysis of their clinical significance and prognosis in the IIIA stage of non-small cell lung cancer. Eur J Cardio Thoracic Surg. 2004;25:502–508.
   PubMed Web of Science ®Google Scholar
• Goya T, Asamura H, Yoshimura H, et al. Prognosis of 6644 resected non-small cell lung cancers in Japan: a Japanese lung cancer registry study. Lung Cancer. 2005;50:227–234.
   PubMed Web of Science ®Google Scholar
• Legras A, Mordant P, Arame A, et al. Long-term survival of patients with pN2 lung cancer according to the pattern of lymphatic spread. Ann Thorac Surg. 2014;97:1156–1162.
   PubMed Web of Science ®Google Scholar
• Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 2009;374:379–386.
   PubMed Web of Science ®Google Scholar
• Donington JS, Pass HI. Surgical resection of non-small cell lung cancer with N2 disease. Thorac Surg Clin. 2014;24:449–456.
   PubMed Web of Science ®Google Scholar
• Garelli E, Renaud S, Falcoz PE, et al. Microscopic N2 disease exhibits a better prognosis in resected non-small-cell lung cancer. Eur J Cardiothorac Surg. 2016;50:322–328.
   PubMed Web of Science ®Google Scholar
• Yazgan S, Ucvet A, Gursoy S, et al. Single-station skip-N2 disease: good prognosis in resected non-small-cell lung cancer (long-term results in skip-N2 disease). Interact Cardiovasc Thorac Surg. 2018;28:247–252.
   Web of Science ®Google Scholar
• Rami-Porta R, Goldstraw P. 25 – The eighth edition of the tumor, node, and metastasis classification of lung cancer. 2nd ed. Amsterdam, Netherlands: Elsevier Inc.; 2018.
   Google Scholar
• Detterbeck FC, Boffa DJ, Kim AW, et al. The eighth edition lung cancer stage classification. Chest. 2017;151:193–203.
   PubMed Web of Science ®Google Scholar
• Prenzel KL, Mönig SP, Sinning JM, et al. Role of skip metastasis to mediastinal lymph nodes in non-small cell lung cancer. J Surg Oncol. 2003;82:256–260.
   PubMed Web of Science ®Google Scholar
• Nakagiri T, Sawabata N, Funaki S, et al. Validation of pN2 sub-classifications in patients with pathological stage IIIA N2 non-small cell lung cancer. Interact Cardiovasc Thorac Surg. 2011;12:733–738.
   PubMed Web of Science ®Google Scholar
• Gorai A, Sakao Y, Kuroda H, et al. The clinicopathological features associated with skip N2 metastases in patients with clinical stage IA non-small-cell lung cancer. Eur J Cardio Thoracic Surg. 2015;47:653–658.
   PubMed Web of Science ®Google Scholar
• Sonobe M, Date H, Wada H, et al. Prognostic factors after complete resection of pN2 non–small cell lung cancer. J Thorac Cardiovasc Surg. 2013;146:788–795.
   PubMed Web of Science ®Google Scholar
• Hanagiri T, Takenaka M, Oka S, et al. Clinical significance in the number of involved lymph nodes in patients that underwent surgery for pathological stage III-N2 non-small cell lung cancer. J Cardiothorac Surg. 2011;6:1–8.
   PubMed Web of Science ®Google Scholar
• Fukuse T, Hirata T, Naiki H, et al. Prognostic significance of proliferative activity in pN2 non-small-cell lung carcinomas and their mediastinal lymph node metastases. Ann Surg. 2000;232:112.
   PubMed Web of Science ®Google Scholar
• Hishida T, Yoshida J, Ohe Y, et al. Surgical outcomes after initial surgery for clinical single-station N2 non-small-cell lung cancer. Jpn J Clin Oncol. 2014;44:85–92.
   PubMed Web of Science ®Google Scholar
• Akçay O. Skip metastasis in non-small cell lung cancer: does it affect the prognosis? Turk Gogus Kalp Dama. 2017;25:230–234.
   Web of Science ®Google Scholar
• Lee J, Kim HK, Park BJ, et al. Recurrence dynamics after trimodality therapy (Neoadjuvant concurrent chemoradiotherapy and surgery) in patients with stage IIIA (N2) lung cancer. Lung Cancer. 2018;115:89–96.
   PubMed Web of Science ®Google Scholar
• Drake JA, Portnoy DC, Tauer K, et al. Adding radiation to adjuvant chemotherapy does not improve survival of patients with N2 lung cancer. Ann Thorac Surg. 2018;106:959–965.
   PubMed Web of Science ®Google Scholar
• Cho HJ, Kim SR, Kim HR, et al. Modern outcome and risk analysis of surgically resected occult N2 non-small cell lung cancer. Ann Thorac Surg. 2014;97:1920–1925.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Non-small cell lung cancer (version 6.2018). 2018. [accessed 2018 Aug 17]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
   Google Scholar
• Lee JG, Lee CY, Park IK, et al. The prognostic significance of multiple station N2 in patients with surgically resected stage IIIA N2 non-small cell lung cancer. J Korean Med Sci. 2008;23:604–608.
   PubMed Web of Science ®Google Scholar
• Thomas DC, Arnold BN, Rosen JE, et al. The significance of upfront knowledge of N2 disease in non-small cell lung cancer. World J Surg. 2018;42:161–171.
   PubMed Web of Science ®Google Scholar